PMID: 7536270May 1, 1995Paper

TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49

The Journal of Urology
P C BrennerP Garin-Chesa

Abstract

Monoclonal antibodies CC49 and B72.3, which recognize a tumor associated glycoprotein (TAG-72) related to sialyted Tn antigen, have been used in clinical trials for radionuclide imaging, and treatment of colon, breast and ovarian carcinoma. In addition, studies with CC49 in patients with metastatic hormone refractory prostate cancer have been initiated based on the observed expression of TAG-72 in primary prostate cancer. We examined whether TAG-72 expression is a common feature of primary, metastatic and hormonally treated prostatic carcinoma. Immunohistochemical analysis of 25 primary prostatic carcinomas confirmed previous data that 21 of 25 specimens (80%) were immunoreactive with CC49. CC49 staining was noted in all 6 well (Gleason score 2 to 4), 8 of 10 moderately (Gleason score 5 to 6) and 7 of 9 poorly (Gleason score 7 to 9) differentiated tumors. CC49 immunoreactivity was noted in 10 of 20 hormonally treated prostate cancers and in 21 of 25 tumors without hormonal therapy. Intense CC49 staining of prostatic intraepithelial neoplasia was present in all 5 specimens examined. In contrast to the primary lesion, many metastatic prostate cancers lacked detectable CC49 immunoreactivity. Of 24 pelvic lymph node metastases from...Continue Reading

References

Apr 1, 1990·American Journal of Obstetrics and Gynecology·A BerchuckR C Bast
Dec 15, 1987·International Journal of Cancer. Journal International Du Cancer·N OhuchiJ Schlom
Dec 1, 1989·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·P Garin-ChesaW J Rettig
May 15, 1983·International Journal of Cancer. Journal International Du Cancer·D StramignoniJ Schlom
Apr 1, 1993·Cancer·R A BadalamentE W Martin

❮ Previous
Next ❯

Citations

Aug 1, 1996·The Prostate·D G BostwickA Lopez-Beltran
Oct 3, 2007·European Journal of Nuclear Medicine and Molecular Imaging·Guozheng LiuDonald J Hnatowich
Apr 7, 2004·Current Oncology Reports·Michael J MorrisHoward I Scher
May 5, 2005·Current Urology Reports·Michael J MorrisHoward I Scher
May 29, 2002·Surgical Oncology·E G HavranekH Pandha
Jul 11, 2001·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·N L SmithA E Wennerberg
Aug 5, 2000·Drugs & Aging·M J PerryA G Dalgleish
Dec 3, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Susan F SlovinHoward I Scher
Dec 6, 2000·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·E M GenegaP B Gaudin
May 25, 2016·Nature Reviews. Urology·Zahid DelwarWilliam Jia
Mar 1, 1997·Biotechnic & Histochemistry : Official Publication of the Biological Stain Commission·R B Myers, W E Grizzle
May 8, 2000·The Journal of Urology·J W Moul

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.